miR-28-5p inhibits cholangiocarcinoma progression and predicts good prognosis of patients

References

• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–1669.
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179.
   PubMed Web of Science ®Google Scholar
• Morise Z, Sugioka A, Hoshimoto S, et al. Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy. J Hepatobiliary Pancreat Surg. 2008;15(5):545–548.
   PubMedGoogle Scholar
• Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2.
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP. Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
   PubMed Web of Science ®Google Scholar
• Tsiakanikas P, Kontos CK, Kerimis D, et al. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. Clin Chem Lab Med. 2018;56(6):990–1000.
   PubMedGoogle Scholar
• Yang M, Yao Y, Eades G, et al. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res Treat. 2011;129(3):983–991.
   PubMed Web of Science ®Google Scholar
• Bartolome-Izquierdo N, de Yebenes VG, Alvarez-Prado AF, et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood. 2017;129(17):2408–2419.
   PubMedGoogle Scholar
• Chen HS, Lu AQ, Yang PY, et al. MicroRNA-28-5p regulates glioma cell proliferation, invasion and migration by targeting SphK1. Eur Rev Med Pharmacol Sci. 2019;23(15):6621–6628.
   PubMedGoogle Scholar
• Wang C, Wu C, Yang Q, et al. miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B. Oncotarget. 2016;7(45):73888–73902.
   PubMedGoogle Scholar
• Xiang DM, Sun W, Zhou T, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut. 2019;68(10):1858–1871.
   PubMedGoogle Scholar
• Xiang D, Cheng Z, Liu H, et al. Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients. Hepatology. 2017;65(5):1566–1580.
   PubMed Web of Science ®Google Scholar
• Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2017;67(9):1704–1715.
   PubMedGoogle Scholar
• Liu S, Jiang J, Huang L, et al. iNOS is associated with tumorigenicity as an independent prognosticator in human intrahepatic cholangiocarcinoma. Cancer Manag Res. 2019;11:8005–8022.
   PubMed Web of Science ®Google Scholar
• Peng DZ, Lu J, Li B, et al. A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma. Gastroenterol Rep (Oxf). 2019;7(5):345–353.
   PubMedGoogle Scholar
• Lee H, Han S, Kwon CS, et al. Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein Cell. 2016;7(2):100–113.
   PubMed Web of Science ®Google Scholar
• Li L, Tang J, Zhang B, et al. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 2015;64(1):156–167.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ma J. miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion. Cancer Biomark. 2019;24(2):173–181.
   PubMed Web of Science ®Google Scholar
• Ursu S, Majid S, Garger C, et al. Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma. Oncogenesis. 2019;8(8):42.
   PubMedGoogle Scholar
• Chhabra R. miRNA and methylation: a multifaceted liaison. Chembiochem. 2015;16(2):195–203.
   PubMed Web of Science ®Google Scholar
• Holubekova V, Mendelova A, Jasek K, et al. Epigenetic regulation by DNA methylation and miRNA molecules in cancer. Future Oncol. 2017;13(25):2217–2222.
   PubMedGoogle Scholar
• Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. World J Gastrointest Oncol. 2019;11(10):842–856.
   PubMed Web of Science ®Google Scholar
• Ghuwalewala S, Ghatak D, Das P, et al. CD44(high)CD24(low) molecular signature determines the cancer stem cell and EMT phenotype in oral squamous cell carcinoma. Stem Cell Res. 2016;16(2):405–417.
   PubMedGoogle Scholar
• Nagaya T, Nakamura Y, Okuyama S, et al. Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-based NIR-PIT. Mol Cancer Res. 2017;15(12):1667–1677.
   PubMed Web of Science ®Google Scholar
• Vega FM, Colmenero-Repiso A, Gomez-Munoz MA, et al. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours. EBioMedicine. 2019;49:82–95.
   PubMed Web of Science ®Google Scholar
• Morine Y, Imura S, Ikemoto T, et al. CD44 expression is a prognostic factor in patients with intrahepatic cholangiocarcinoma after surgical resection. Anticancer Res. 2017;37(10):5701–5705.
   PubMedGoogle Scholar
• Thanee M, Loilome W, Techasen A, et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment. Cancer Sci. 2016;107(7):991–1000.
   PubMed Web of Science ®Google Scholar
• Suwannakul N, Ma N, Thanan R, et al. Overexpression of CD44 variant 9: a novel cancer stem cell marker in human cholangiocarcinoma in relation to inflammation. Mediators Inflamm. 2018;2018:4867234.
   PubMedGoogle Scholar